Parabilis Medicines Announces Largest IPO in Biotech History - $670M

The Parabilis IPO is a good indicator of the health of the biotech and healthcare sector as it comes out of the doldrums in what has been an active M&A start to 2026.

Parabilis Medicines completed the largest biotech IPO on record, initially pricing an upsized $670 million IPO at $20/share, above the proposed range.

After the underwriters fully exercised their option, Parabilis raised $770.5 million from the IPO, plus ~$75 million from a concurrent private placement to Regeneron. Parabilis says it has raised over $1.2 billion in 2026 across public/private financings and strategic collaborations.

The company is focused on “historically undruggable” protein targets through its Helicon™ stabilized helical peptide platform, with lead program FOG-001 / zolucatetide targeting the β-catenin:TCF interaction in Wnt/β-catenin-driven cancers.

Theme	Why it matters
IPO window reopening	Large biotech IPOs are getting done again, but the market remains selective.
Platform + lead asset matters	Investors appear willing to fund companies with both a differentiated platform and a defined clinical path.
Oncology remains favored	Cancer remains one of the strongest biotech financing categories because of high unmet need and large commercial markets.
Strategic validation counts	Regeneron’s concurrent investment adds credibility beyond public-market demand.
Capital intensity is high	A record IPO also reflects how expensive late-stage biotech development has become.

While not quite SpaceX size, having some of the largest ever biotech IPOs this year is a positive indicator for the health of the sector.